Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Fosun Pharmaceutical has announced that its subsidiary’s drug registration application for Raltitrexed for Injection has been accepted by the National Medical Products Administration. This new chemical drug is intended as a treatment for advanced colorectal cancer in patients unsuitable for certain combination chemotherapies. The company has invested approximately RMB2.96 million in the drug’s research and development.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
